Artara Therapeutics Inc (TARA)

$3.06 -0.04 (-1.29%)
Market Cap 118.06M
Revenue (ttm) 0.00
Net Income (ttm) -44.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 301,800
Avg Vol 342,042
Day's Range N/A - N/A
Shares Out 38.58M
Stochastic %K 9%
Beta 1.42
Analysts Strong Sell
Price Target $21.86

Company Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving pare...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 844 0337
Address:
345 Park Avenue South, 3rd Floor, New York, United States
RakeTheProfit
RakeTheProfit Jul. 28 at 11:42 PM
$TARA starting to see some movement here. Readouts coming soon.
1 · Reply
thenumbersdontlie
thenumbersdontlie Jul. 28 at 6:38 PM
$TARA LM data?
0 · Reply
M4dRizzl
M4dRizzl Jul. 24 at 2:45 PM
$TARA Momentum is building up, August looks promising
0 · Reply
Drugtrade
Drugtrade Jul. 21 at 6:23 PM
$TARA hope you got in under $2.. would not be surprised to see this one trend up from now on at least until market correction. Can you tell me when that will occur?
2 · Reply
AndriiLarik
AndriiLarik Jul. 16 at 2:28 AM
$TARA I following this company since December 2024,and I think August will be interesting for this company.
1 · Reply
AndriiLarik
AndriiLarik Jul. 14 at 8:43 PM
$TARA
0 · Reply
Drugtrade
Drugtrade Jul. 8 at 5:19 PM
$TARA who cares about penny or even dollar swings considering long term outlook and possible buyout price target .. 100 shares long is infinitely better than zero shares
0 · Reply
MCMI
MCMI Jul. 4 at 11:32 PM
$TARA Happy Independence Day!!
0 · Reply
Gurss
Gurss Jul. 2 at 7:22 PM
$TARA , get it
0 · Reply
Rolo2024
Rolo2024 Jul. 1 at 8:42 PM
$TARA Can anyone tell me why most seem Bullish on this stock? All I have been seeing is a steady downward trend and no good news coming out?
1 · Reply
Latest News on TARA
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 4:08 PM EDT - 2 days ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics Announces Addition to the Russell 3000® Index

Jun 30, 2025, 8:00 AM EDT - 4 weeks ago

Protara Therapeutics Announces Addition to the Russell 3000® Index

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

Jun 2, 2025, 4:04 PM EDT - 2 months ago

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

Protara Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2025, 8:00 AM EDT - 2 months ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:00 AM EDT - 3 months ago

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Apr 26, 2025, 10:00 AM EDT - 3 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Apr 23, 2025, 8:00 AM EDT - 3 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Apr 15, 2025, 4:13 PM EDT - 3 months ago

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Apr 10, 2025, 4:05 PM EDT - 4 months ago

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Mar 28, 2025, 5:10 PM EDT - 4 months ago

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Mar 19, 2025, 8:00 AM EDT - 4 months ago

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 5, 2025, 8:00 AM EST - 5 months ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 5 months ago

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Jan 13, 2025, 8:00 AM EST - 7 months ago

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Protara Therapeutics: Rising From The Ashes

Dec 14, 2024, 8:30 AM EST - 8 months ago

Protara Therapeutics: Rising From The Ashes

Protara Announces Closing of $100 Million Public Offering

Dec 11, 2024, 4:05 PM EST - 8 months ago

Protara Announces Closing of $100 Million Public Offering

Protara Therapeutics: Carving New Roads In Bladder Cancer

Dec 10, 2024, 5:00 PM EST - 8 months ago

Protara Therapeutics: Carving New Roads In Bladder Cancer

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Dec 10, 2024, 3:55 PM EST - 8 months ago

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Protara Announces Pricing of $100 Million Public Offering

Dec 9, 2024, 11:35 PM EST - 8 months ago

Protara Announces Pricing of $100 Million Public Offering

Protara Announces Proposed Public Offering

Dec 9, 2024, 4:01 PM EST - 8 months ago

Protara Announces Proposed Public Offering

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Dec 5, 2024, 10:50 AM EST - 8 months ago

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Nov 15, 2024, 5:52 PM EST - 9 months ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Nov 6, 2024, 8:00 AM EST - 9 months ago

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Oct 21, 2024, 8:00 AM EDT - 10 months ago

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 9, 2024, 8:05 AM EDT - 11 months ago

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Sep 9, 2024, 8:00 AM EDT - 11 months ago

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 24, 2024, 5:06 PM EDT - 1 year ago

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Apr 5, 2024, 8:04 AM EDT - 1 year ago

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Apr 5, 2024, 8:02 AM EDT - 1 year ago

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22, 2024, 8:55 AM EST - 1 year ago

Protara: A Bombed Out Biotech With A Very Positive Skew

CGON

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Nov 30, 2023, 8:30 AM EST - 1 year ago

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Nov 3, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Sep 20, 2023, 8:30 AM EDT - 2 years ago

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 7:30 AM EDT - 2 years ago

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

May 4, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

May 2, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 8, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

Feb 2, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

Jan 30, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

Dec 1, 2022, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview

Nov 3, 2022, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview

RakeTheProfit
RakeTheProfit Jul. 28 at 11:42 PM
$TARA starting to see some movement here. Readouts coming soon.
1 · Reply
thenumbersdontlie
thenumbersdontlie Jul. 28 at 6:38 PM
$TARA LM data?
0 · Reply
M4dRizzl
M4dRizzl Jul. 24 at 2:45 PM
$TARA Momentum is building up, August looks promising
0 · Reply
Drugtrade
Drugtrade Jul. 21 at 6:23 PM
$TARA hope you got in under $2.. would not be surprised to see this one trend up from now on at least until market correction. Can you tell me when that will occur?
2 · Reply
AndriiLarik
AndriiLarik Jul. 16 at 2:28 AM
$TARA I following this company since December 2024,and I think August will be interesting for this company.
1 · Reply
AndriiLarik
AndriiLarik Jul. 14 at 8:43 PM
$TARA
0 · Reply
Drugtrade
Drugtrade Jul. 8 at 5:19 PM
$TARA who cares about penny or even dollar swings considering long term outlook and possible buyout price target .. 100 shares long is infinitely better than zero shares
0 · Reply
MCMI
MCMI Jul. 4 at 11:32 PM
$TARA Happy Independence Day!!
0 · Reply
Gurss
Gurss Jul. 2 at 7:22 PM
$TARA , get it
0 · Reply
Rolo2024
Rolo2024 Jul. 1 at 8:42 PM
$TARA Can anyone tell me why most seem Bullish on this stock? All I have been seeing is a steady downward trend and no good news coming out?
1 · Reply
pablo4
pablo4 Jul. 1 at 7:31 PM
$TARA
0 · Reply
M4dRizzl
M4dRizzl Jul. 1 at 12:09 PM
$TARA
0 · Reply
Gurss
Gurss Jun. 30 at 5:11 PM
$TARA
0 · Reply
thenumbersdontlie
thenumbersdontlie Jun. 27 at 8:01 PM
$TARA 2.6m lot at close?
1 · Reply
justiceforb_85
justiceforb_85 Jun. 23 at 7:56 PM
$TARA added on this dip.
0 · Reply
Drugtrade
Drugtrade Jun. 12 at 6:21 PM
$TARA added a few .. plenty of time. Dip to $2 already so i can pull port
0 · Reply
Traderphil2023
Traderphil2023 Jun. 11 at 8:04 PM
$TARA looks like all the bios on my list, including XBI was down today
0 · Reply
RakeTheProfit
RakeTheProfit Jun. 6 at 2:56 PM
$TARA Everyone still sleeping on this ticker.
1 · Reply
jayjaycops
jayjaycops Jun. 5 at 6:04 PM
$TARA hopefully loaded 5k shares
0 · Reply
TwongStocks
TwongStocks Jun. 4 at 8:16 PM
$TARA William Conkling, the new CCO, was awarded 50,000 RSUs and 200,000 options with a $3.30 exercise price. https://www.sec.gov/Archives/edgar/data/1359931/000121390025051157/xslF345X05/ownership.xml
0 · Reply
QuiverQuant
QuiverQuant Jun. 2 at 9:50 PM
Protara Therapeutics Appoints William Conkling as Chief Commercial Officer Read more on $TARA: https://www.quiverquant.com/news/Protara+Therapeutics+Appoints+William+Conkling+as+Chief+Commercial+Officer
0 · Reply
GJC1978
GJC1978 Jun. 2 at 6:59 PM
$TARA come on back to 3.70
0 · Reply